CellWell record HH-352742
Utilization of fezolinetant for the treatment of moderate-to-severe vasomotor symptoms of menopause in a real-world setting
Christine D Hsu; Rebecca M. Carpenter; Gwyn Richardson; Fangjian Guo; Victor Adekanmbi; Thao N Hoang; A. Berenson
Menopause ยท 2026
In plain language
Among 9,853 women prescribed fezolinetant for vasomotor symptoms, 20.5% maintained use beyond initial prescription, with suboptimal liver monitoring in early treatment.
- Evidence
- Emerging
- Design
- Primary research (design unspecified)
Cite this record: https://thecellwell.org/studies/HH-352742
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.